NovaBay Pharmaceuticals, Inc.

DB:B9P0 Stock Report

Market Cap: €2.3m

NovaBay Pharmaceuticals Valuation

Is B9P0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of B9P0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate B9P0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate B9P0's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for B9P0?

Key metric: As B9P0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for B9P0. This is calculated by dividing B9P0's market cap by their current revenue.
What is B9P0's PS Ratio?
PS Ratio0.2x
SalesUS$13.88m
Market CapUS$2.53m

Price to Sales Ratio vs Peers

How does B9P0's PS Ratio compare to its peers?

The above table shows the PS ratio for B9P0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.3x
B8FK Biofrontera
0.8xn/a€16.4m
VP2 Valeo Pharma
0.01x20.9%€493.4k
SBX SynBiotic
7.2x39.7%€27.9m
0RX Redx Pharma
13.3x-37.6%€65.0m
B9P0 NovaBay Pharmaceuticals
0.2x7.5%€2.5m

Price-To-Sales vs Peers: B9P0 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (13.6x).


Price to Sales Ratio vs Industry

How does B9P0's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x3.4%
B9P0 NovaBay Pharmaceuticals
0.2x7.5%US$2.53m
B9P0 0.2xIndustry Avg. 2.9xNo. of Companies35PS0612182430+
23 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x21.4%
B9P0 NovaBay Pharmaceuticals
0.2x90.2%US$2.53m
No more companies

Price-To-Sales vs Industry: B9P0 is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Pharmaceuticals industry average (4.4x).


Price to Sales Ratio vs Fair Ratio

What is B9P0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

B9P0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate B9P0's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies